Loading...
XTAI
1707
Market cap422mUSD
Jul 09, Last price  
91.60TWD
1D
0.66%
1Q
-23.67%
Jan 2017
-51.02%
Name

Grape King Bio Ltd

Chart & Performance

D1W1MN
XTAI:1707 chart
P/E
11.14
P/S
1.32
EPS
8.22
Div Yield, %
7.53%
Shrs. gr., 5y
10.59%
Rev. gr., 5y
2.26%
Revenues
10.25b
-8.14%
1,489,681,0001,702,107,0002,112,457,0002,821,859,0003,282,274,0003,771,021,0004,611,719,0005,652,413,0006,282,859,0007,247,855,0009,185,021,0009,388,128,0009,183,321,0009,239,070,0009,168,195,0009,798,246,00010,391,231,00010,635,464,00011,160,005,00010,251,607,000
Net income
1.22b
-15.88%
150,422,000180,871,000164,522,000379,341,000427,700,000473,062,000618,902,000835,762,000942,483,0001,051,652,0001,296,769,0001,351,941,0001,295,394,0001,938,566,0001,895,095,0001,947,989,0002,169,687,0001,452,728,0001,448,299,0001,218,305,000
CFO
2.18b
+16.20%
468,842,000253,111,000434,852,000720,611,000683,894,000848,526,0001,121,257,0001,575,779,0001,701,422,0001,306,930,0002,803,128,0002,495,656,0002,417,429,0002,171,439,0002,719,190,0002,542,204,0002,990,437,0002,519,402,0001,875,912,0002,179,812,000
Dividend
Jun 17, 20263.8 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Grape King Bio Ltd. is a Taiwanese enterprise specializing in the production and distribution of a diverse array of health-focused items, encompassing pharmaceuticals, traditional remedies, nourishing beverages, and dietary supplements. Its market presence spans Taiwan, mainland China, and various international regions. The company engages with customers through multiple operational avenues, including multi-level marketing channels, conventional distribution networks, and a significant original design and equipment manufacturing (ODM/OEM) division. Among its extensive product range are various mushroom mycelium derivatives, notably ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor. Additionally, it formulates and supplies probiotics featuring strains like enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium, alongside a selection of enzyme products. Beyond its own brand, Grape King Bio offers comprehensive contract services, such as original equipment manufacturing (OEM), original design manufacturing (ODM), custom formulation development, dedicated research and development support, and the provision of raw materials. Established in 1969, the firm maintains its corporate headquarters in Taoyuan City, Taiwan.
IPO date
Dec 20, 1982
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT